# Bionano Genomics Inc. (BNGO)

Source: https://www.quantisnow.com/company/BNGO
Generated: 2026-11-22T00:50:41.863Z

- Ticker: BNGO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Laboratory Analytical Instruments
- IPO year: 2018
- SEC CIK: 0001411690
- Website: bionanogenomics.com

## About

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

## Latest BNGO news and filings

- 2026-11-16 18:32 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-bionano-genomics-inc-6793597)
- 2026-11-10 21:11 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bionano-genomics-inc-6784048)
- 2026-11-10 21:05 UTC [Earnings] [Bionano Reports Third Quarter 2026 Results and Provides a Business Update](https://www.quantisnow.com/insight/bionano-reports-third-quarter-2026-results-and-provides-a-business-6783805)
- 2026-11-10 21:03 UTC [SEC Form 8-K] [Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionano-genomics-inc-filed-sec-form-8-k-results-of-operations-6783785)
- 2026-11-06 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bionano-genomics-inc-6777773)
- 2026-11-06 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-bionano-genomics-inc-6777771)
- 2026-11-05 22:13 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-bionano-genomics-inc-6777347)
- 2026-11-05 22:11 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-bionano-genomics-inc-6777337)
- 2026-10-30 22:22 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-bionano-genomics-inc-6765853)
- 2026-10-27 21:13 UTC [SEC Form S-1] [SEC Form S-1 filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-bionano-genomics-inc-6759696)
- 2026-10-27 20:05 UTC [Earnings Date] [Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026](https://www.quantisnow.com/insight/bionano-to-report-third-quarter-2026-financial-results-and-host-6759124)
- 2026-10-19 18:27 UTC [SEC Form SCHEDULE 13G filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-bionano-genomics-inc-6750431)
- 2026-09-23 13:00 UTC [Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies](https://www.quantisnow.com/insight/bionano-laboratories-announces-expansion-of-diagnostic-testing-based-on-optical-6723838)
- 2026-09-14 13:00 UTC [Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia](https://www.quantisnow.com/insight/bionano-announces-three-new-peer-reviewed-studies-demonstrate-clinical-value-of-6713950)
- 2026-09-14 12:30 UTC [SEC Form 8-K] [Bionano Genomics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionano-genomics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6713880)
- 2026-09-10 13:00 UTC [Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms](https://www.quantisnow.com/insight/bionano-laboratories-announces-proposed-local-coverage-determination-lcd-from-moldx-6711117)
- 2026-09-09 20:30 UTC [Insider Buy] [Interim Chief Executive Luderer Albert bought $4,845 worth of shares (4,000 units at $1.21) (SEC Form 4)](https://www.quantisnow.com/insight/interim-chief-executive-luderer-albert-bought-4845-worth-of-shares-6710171)
- 2026-09-08 13:00 UTC [Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping](https://www.quantisnow.com/insight/bionano-laboratories-announces-new-york-state-department-of-health-approval-6707792)
- 2026-08-24 12:00 UTC [Conference Announcement] [Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference](https://www.quantisnow.com/insight/bionano-to-participate-in-the-hc-wainwright-28th-annual-global-6692117)
- 2026-08-21 20:30 UTC [Insider Buy] [Interim Chief Executive Luderer Albert bought $4,860 worth of shares (4,000 units at $1.22) (SEC Form 4)](https://www.quantisnow.com/insight/interim-chief-executive-luderer-albert-bought-4860-worth-of-shares-6691468)
- 2026-08-10 20:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Bionano Genomics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bionano-genomics-inc-6673710)
- 2026-08-10 20:05 UTC [SEC Form 8-K] [Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionano-genomics-inc-filed-sec-form-8-k-results-of-operations-6673599)
- 2026-08-10 20:05 UTC [Earnings Date] [Bionano Reports Second Quarter 2026 Results and Provides a Business Update](https://www.quantisnow.com/insight/bionano-reports-second-quarter-2026-results-and-provides-a-business-6673557)
- 2026-08-05 21:28 UTC [SEC Form 4] [SEC Form 4 filed by Principal Accounting Officer Adamchak Mark](https://www.quantisnow.com/insight/sec-form-4-filed-by-principal-accounting-officer-adamchak-mark-6666413)
- 2026-08-05 21:27 UTC [SEC Form 4] [SEC Form 4 filed by General Counsel Dixon Jonathan V.](https://www.quantisnow.com/insight/sec-form-4-filed-by-general-counsel-dixon-jonathan-v-6666406)
- 2026-08-05 21:27 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer Oldakowski Mark](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer-oldakowski-mark-6666399)
- 2026-08-05 21:26 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Hastie Alex Reid](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-hastie-alex-6666397)
- 2026-08-05 20:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Oldakowski Mark](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-oldakowski-mark-6664795)
- 2026-08-05 20:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hastie Alex Reid](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hastie-alex-reid-6664780)
- 2026-08-05 20:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Adamchak Mark](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-adamchak-mark-6664779)
- 2026-08-05 20:00 UTC [SEC Form 3] [SEC Form 3 filed by new insider Dixon Jonathan V.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-dixon-jonathan-v-6664778)
- 2026-07-30 20:43 UTC [SEC Form 3] [New insider Hastie Alex Reid claimed ownership of 63 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-hastie-alex-reid-claimed-ownership-of-63-shares-6656491)
- 2026-07-27 20:05 UTC [Earnings Date] [Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026](https://www.quantisnow.com/insight/bionano-to-report-second-quarter-2026-financial-results-and-host-6649584)
- 2026-06-24 12:30 UTC [SEC Form 8-K] [Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bionano-genomics-inc-filed-sec-form-8-k-other-events-financial-6613662)
- 2026-06-24 12:30 UTC [Leadership Update] [Bionano Announces Hiring of Chief Scientific Officer](https://www.quantisnow.com/insight/bionano-announces-hiring-of-chief-scientific-officer-6613655)
- 2026-06-18 12:00 UTC [Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption](https://www.quantisnow.com/insight/bionano-announces-67-year-over-year-growth-in-studies-featuring-optical-genome-6607922)
- 2026-06-11 12:00 UTC [Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders](https://www.quantisnow.com/insight/bionano-announces-multiple-publications-in-2026-describing-unique-utility-of-6598224)
- 2026-06-05 20:00 UTC [SEC Form 8-K] [Bionano Genomics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/bionano-genomics-inc-filed-sec-form-8-k-leadership-update-6591039)
- 2026-06-04 00:52 UTC [SEC Form 4] [GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 24 shares, decreasing direct ownership by 9% to 239 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/general-counsel-dixon-jonathan-v-covered-exercisetax-liability-with-24-6588253)
- 2026-06-04 00:51 UTC [SEC Form 4] [CHIEF OPERATING OFFICER Oldakowski Mark covered exercise/tax liability with 27 shares, decreasing direct ownership by 3% to 868 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-operating-officer-oldakowski-mark-covered-exercisetax-liability-with-27-6588251)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BNGO
- Earnings history: https://www.quantisnow.com/earnings/BNGO
- Dividend history: https://www.quantisnow.com/dividends/BNGO
- Insider transactions: https://www.quantisnow.com/insiders/BNGO
- Options chain: https://www.quantisnow.com/options/BNGO
- SEC 8-K filings only: https://www.quantisnow.com/company/BNGO/8-k
- RSS and alerts for BNGO: https://www.quantisnow.com/docs/rss-feeds.md
